Immunotherapy with interleukin-2 after autologous bone marrow transplantation (ABMT) for acute myelogenous leukemia (AML).

被引：0
|
作者：
Massumoto, CM [1 ]
Macedo, MCA [1 ]
Saboya, R [1 ]
Silva, R [1 ]
Loterio, H [1 ]
Dzik, C [1 ]
Pallotta, R [1 ]
Chamone, DAF [1 ]
Dulley, F [1 ]
机构：
[1] UNIV SAO PAULO,FUNDACAO PRO SANGUE HEMOCENTRO,DEPT HAEMATOL,BR-05508 SAO PAULO,BRAZIL
来源：
BLOOD | 1997年 / 90卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4566 / 4566
页数：1
相关论文
共 50 条
  • [21] AUTOIMMUNE HEMOLYTIC-ANEMIA IN A PATIENT WITH ACUTE MYELOGENOUS LEUKEMIA TREATED WITH LOW-DOSE INTERLEUKIN-2 AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION
    MELONI, G
    ANDRIZZI, C
    VIGNETTI, M
    GIRELLI, G
    MANDELLI, F
    BLOOD, 1995, 86 (02) : 837 - 838
  • [22] Celiac disease presented after autologous bone marrow transplantation for acute myelogenous leukemia
    Valizadeh, Nasim
    Shateri, Kamran
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2013, 34 (02)
  • [23] Myeloablative therapy with autologous bone marrow transplantation (ABMT) as consolidation of first remission in younger patients with acute myelogenous leukaemia (AML)
    Rohatiner, AZS
    Bassan, R
    Raymondi, R
    Amess, JAL
    Carter, M
    Rodeghiero, F
    Barbui, T
    Lister, TA
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 848 - 848
  • [24] Myeloablative therapy with autologous bone marrow transplantation (ABMT) as consolidation of first remission in younger patients with acute myelogenous leukaemia (AML)
    Slater, SE
    Rohatiner, AZS
    Bassan, R
    Raimondi, R
    Amess, J
    Carter, M
    Arnott, S
    Personen, A
    Rodeghiero, F
    Barbui, T
    Lister, TA
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (01) : 107 - 107
  • [25] Malignant karyotype predicts outcome after but not before autologous bone marrow transplantation (ABMT) in transplant candidates with acute myeloid leukemia (AML)
    Imrie, K
    Prince, HM
    Dube, I
    Crump, M
    Stewart, AK
    Keating, A
    BLOOD, 1995, 86 (10) : 157 - 157
  • [26] Prediction of therapy-related acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) after autologous bone marrow transplant (ABMT) for lymphoma.
    Legare, RD
    Gribben, JG
    Nadler, LM
    Gilliland, DG
    BLOOD, 1995, 86 (10) : 1586 - 1586
  • [27] The incidence and significance of acquired cytogenetic abnormalities following autologous bone marrow transplantation (ABMT) for acute myeloid leukemia (AML)
    Imrie, K
    Dube, I
    Prince, HM
    Keating, A
    BLOOD, 1995, 86 (10) : 3786 - 3786
  • [28] Comparative study of autologous bone marrow (ABMT) and autologous peripheral blood progenitor cell transplantation (PBPCT) in acute myeloid leukemia (AML)
    Demuynck, H
    Verhoef, GEG
    Maertens, J
    Vandenberghe, P
    Zachee, P
    Boogaerts, MA
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 309 - 309
  • [29] LEUKEMIA ANTIGENS IN ACUTE MYELOGENOUS LEUKEMIA (AML) TREATED BY BONE-MARROW TRANSPLANTATION
    RUSSELL, EC
    MOHANAKUMAR, T
    DUNN, NL
    MCWILLIAMS, NB
    MAURER, HM
    PEDIATRIC RESEARCH, 1980, 14 (04) : 539 - 539
  • [30] INTERLEUKIN-2 AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION AS CONSOLIDATIVE IMMUNOTHERAPY AGAINST MINIMAL RESIDUAL DISEASE
    BOSLY, A
    BRICE, P
    HUMBLET, Y
    DOYEN, C
    FAILLE, A
    CHATELAIN, B
    FRANKS, C
    GISSELBRECHT, C
    SYMANN, M
    NOUVELLE REVUE FRANCAISE D HEMATOLOGIE, 1990, 32 (01): : 13 - 16
12345